ICV San Francisco 2018: Healthcare Innovation Forum at UCSF

January 11

ICV San Francisco 2018: Healthcare Innovation Forum at UCSF

January 11

ICV San Francisco 2018: Healthcare Innovation Forum at UCSF

January 11

Innovative research is leading to breakthroughs in medicines, therapies, devices, and technologies which will define the future of healthcare. There will be new treatments capable of curing a myriad of illnesses, thus helping people to live longer, with less pain. Through careful investing, countless lives can be profoundly improved.

At ICV San Francisco 2018 at UCSF, we will host a series of presentations where change-makers and forward-thinking leaders will share their ideas and evaluate opportunities to solve some of the most complex challenges in human health.

UCSF: Caring, Healing, Teaching and Discovering

This highly-exclusive and carefully curated event will be hosted at University of California, San Francisco (UCSF), a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences; and a preeminent biomedical research enterprise. It also includes UCSF Health, which comprises two top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children’s Hospital San Francisco, and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.

ARVE Error: Mode: lazyload not available (ARVE Pro not active?), switching to normal mode

“The doctor of the future will give no medication, but will interest his patients in the care of human frame, diet and in the cause and prevention of disease.”

– Thomas Edison

Leadership Spotlight: Mark Laret

Under his leadership, UCSF Medical Center reversed what had been a $60 million annual loss in 2000 and within five years produced a $70 million annual gain. Strong financial performance has enabled the self-supporting, nonprofit medical center to pursue expansion and modernization of its facilities and equipment and make advances in quality of care, patient safety and patient satisfaction.

Mark R. Laret is president and chief executive officer of UCSF Health, which is comprised of Benioff Children’s Hospitals San Francisco and Oakland, Langley Porter Psychiatric Hospital and Clinics and the Faculty Practice. Laret, who joined UCSF in 2000, is a 30-year veteran of health care management and a national leader in health care reform. His career began at UCLA Medical Center, where he served from 1980 to 1995 in several leadership positions, before being named CEO of UC Irvine Medical Center, which he led from 1995 to 2000.As CEO of UCSF Medical Center and UCSF Benioff Children’s Hospitals, Laret heads one of the most distinguished medical institutions in the world, one that is consistently ranked by U.S. News & World Report as one of the top hospitals in the United States and as the best in Northern California. At UCSF, he has led initiatives to improve quality of care and patient safety and to modernize facilities and equipment. He led an effort to build a $1.5 billion UCSF hospital complex at the Mission Bay campus — including hospitals for children, women’s services and cancer — and raised $600 million in private contributions for the new facility.

Jim Burness is General Partner of Inovation Ventures.With more than 20 years of board and management advisory experience, Jim builds a wide range of drug development, drug delivery, medical device and diagnostic companies and guides them to exit. He is a senior strategic advisor with particular focus on financings and capital formation, having raised over $125M, corporate partnerships, board creation, strategic direction and corporate governance. Jim pushes companies forward, creating value and building solid foundations for growth with an extensive network encompassing VCs, Investment Bankers and Pharma B/D.

Big Ideas to Market

UC San Francisco strives to translate our scientific discoveries for public use and benefit. Whether it’s a new drug molecule, diagnostic, medical device or digital health application, the goal UCSF is to ensure the best new therapies and technologies can make their way to the patient as efficiently and safely as possible. UCSF Innovation Ventures creates new models for bringing our innovations to market by fostering entrepreneurship among our researchers and clinicians, as well as partnering with industry leaders to accelerate solutions that can directly improve health. One aim of UCSF Innovation Ventures is to keep inventions from languishing on companies’ shelves, which often occurs when firms license early-stage inventions but do not invest the necessary resources to develop them. Another is to increase the licensing revenues earned by UCSF inventions: companies are likely to pay more for innovations with more proven value.

Barry Selick, PhD is Vice Chancellor for Business Development, Innovation and Partnerships of UCSF Innovation Ventures, where he oversees proof-of-concept studies of promising UCSF life science inventions – which encompass drug molecules, device prototypes, digital health applications, and more – to gather evidence on which inventions are most likely to help patients as new therapies, diagnostics or software. Dr. Selick also serves as Chairman of the Board of Catalyst Biosciences (CBIO) and Threshold Pharmaceuticals (THLD) after serving as the company’s Chief Executive Officer from June 2002 to April 2017, at which time he became a Vice Chancellor at UCSF. From June 2002 to July 2007, he was a Venture Partner of Sofinnova Ventures, a venture capital firm. From January 1999 to April 2002, Dr. Selick was Chief Executive Officer of Camitro Corporation, a biotechnology company as well as founder and Chairman of Camitro UK, a wholly-owned subsidiary of Camitro Corporation. Prior to Camitro, Dr. Selick was at Affymax Research Institute, most recently as Vice President of Research, where he directed activities in combinatorial chemistry-based drug discovery and technology development. Dr. Selick was a successful scientist and one of the earliest employees of Protein Design Labs, where he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that technology to PDL’s first product, Zenapax, which was developed and commercialized by Roche for the prevention of kidney transplant rejection. He was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

Thomas Quinlan is Partner of ReedSmith. Tom is an experienced corporate partner who advises emerging and established technology, healthcare and life science companies. He has organized numerous businesses and joint ventures in many jurisdictions and has advised Boards and management on corporate governance and shareholder rights. Tom has acted as outside general counsel for many private companies. Tom is an experienced corporate partner who advises emerging and established technology, healthcare and life science companies. He has organized numerous businesses and joint ventures in many jurisdictions and has advised Boards and management on corporate governance and shareholder rights. Tom has acted as outside general counsel for many private companies.

Neuroscience of Depression | Addiction

The Center for Integrative Neuroscience was established at UC San Francisco in 1990. Within the Center, more than 80 scientists in 13 laboratories are discovering how we see and hear, how we move our limbs, why we feel pain, how we learn and remember, and how we speak and understand language. Research is focused on questions of how the nerve cells in brains work together to generate human behaviors, rather than on the operation of the nerve cells themselves. Approaches in use in the Center include the rigorous analysis of behavior, measurements of the electrical activity of individual brain cells, imaging of brain tissue with modern microscopic techniques, computer modeling, and other theoretical approaches to brain function. Research provides the foundation for applications to human neurological disease for disorders ranging from tremor to learning disabilities.

ARVE Error: Mode: lazyload not available (ARVE Pro not active?), switching to normal mode

Josh Berke, PhD is Professor for UCSF School of Medicine. Berke Lab at UCSF investigates brain mechanisms involved in learning, motivation and decision-making, and how these mechanisms go awry in disorders such as drug addiction, Parkinson’s Disease and Huntington’s Disease. (see www.berkelab.org). He is also Director of the Alcohol and Addiction Research Group, and holds the Rudi Schmid Distinguished Professorship in Neurology.

Andrew Krystal, MD is inaugural Executive Vice Chair for the Langley Porter Psychiatric Institute (LPPI) at UCSF. He has extensive experience working with patients with mood disorders both clinically and in research studies that will be a key asset to the proposed effort, as well as nearly 30 years of experiencing treating patients with mood disorders. He also carried out fundamental work on the personalization of therapies for the treatment of patients with mood disorders and the development of novel therapies for these conditions.

Danielle Ramo, PhD is Assistant Professor and licensed psychologist in the Department of Psychiatry and the Helen Diller Family Comprehensive Cancer Center at UCSF. She directs the Research on Addictions and Digital Interventions Lab, and co-directs the Psychiatry Digital Health Core. Her research program focuses on using digital media to understand and address risky drug and alcohol use. Dr. Ramo has developed the Tobacco Status Project social media intervention to help young adults quit smoking, and is leading three clinical trials testing the efficacy of social media-mediated treatment to reduce substance use in young adults. Additional studies are examining patterns and toxicology of electronic-cigarette use in adolescents and tobacco and marijuana co-use in a changing policy landscape. Her research has demonstrated the high prevalence of tobacco and marijuana co-use, associations between co-use and smoking, and differences in motivation and thoughts about abstinence for the two substances in co-users. Her funding includes awards from the National Institute on Drug Abuse (K23, R34, R21), and the California Tobacco-Related Diseases Research Program (fellowship, High Impact Project awards).

Shawn Singh is CEO and Director of VistaGen Therapeutics. He joined Vistagen Therapeutics’ Board of Directors in 2000 and served on our management team (part-time) from late-2003, following our acquisition of Artemis Neuroscience, of which he was President, to August 2009. Mr. Singh has over 25 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO), serving in numerous senior management roles. Prior to joining VistaGen as Chief Executive Officer, Mr. Singh served as Managing Principal of Cato BioVentures, a healthcare-focused venture capital firm, and as Chief Business Officer and General Counsel of Cato Research Ltd, a profitable global CRO affiliated with Cato BioVentures. Earlier, Mr. Singh served as Chief Business Officer of SciClone Pharmaceuticals (NASDAQ: SCLN), a US-based, China-focused specialty pharmaceutical company with a substantial revenue-generating and profitable commercial business and a marketed product portfolio of differentiated therapies for oncology, infectious diseases and cardiovascular disorders.

Vikaas Sohal, MD, PhD is Associate Professor, Psychiatry of the UCSF Center for Integrative Neuroscience. Research focus is to study circuits in the prefrontal cortex in order to understand (1) how the properties of individual prefrontal neurons, their inputs, and their interconnections give rise to emergent patterns of circuit activity, and (2) how these patterns of activity contribute to both normal cognition and the pathological behaviors associated with neuropsychiatric disorders such as schizophrenia and autism.

Virtual Reality, Real Science

Imagine having the choice to play a video game instead of taking a drug to improve your brain health. Envision using virtual reality to reduce the need for opioids during surgery. Come explore UCSF’s Neuroscape Lab, which uses cutting-edge technologies to optimize our cognition and memory and address the challenges of ADHD, autism, and depression. Use virtual reality to fly through a human brain, and witness how a surgeon will use augmented reality to visualize a patient’s tumor in real time to remove it safely and effectively.

Joaquin Anguera, PhD is Associate Professor in Neurology, Physiology and Psychiatry at UCSF. The body of research Dr. Anguera has developed during his graduate and postdoctoral training has focused on characterizing & augmenting aspects of skill acquisition & cognitive control. The approach he has taken in studying these domains has involved a strong interdisciplinary component that bridges aspects of motor learning and psychology in healthy young and older adults, with more recent efforts centering on depressed individuals as well as ethnic minorities. His current work leverages state-of-the-art technological approaches to create i) advanced training tools to remediate cognitive deficiencies (see the cover story in Nature, Anguera et al., 2013) and ii) sophisticated approaches using mobile technology to robustly characterizing individual abilities outside of the laboratory.

Autism and the Brain

Helen Willsey, PhD is interested in understanding how Autism Spectrum Disorder (ASD)-associated genes function during neurodevelopment. Despite the genetic heterogeneity of ASD, several lines of evidence suggest that ASD-associated genes share common molecular underpinnings. To identify these common mechanisms, Helen leverages CRISPR/Cas9 genome editing with the diploid frog model Xenopus tropicalis. Due to the speed of frog development, Helen can rapidly study the loss of function phenotype of many ASD genes in parallel. Specifically, she injects Cas9 protein and a single guide RNA (sgRNA) against an ASD gene at the two-cell embryo stage, generating animals in which exactly half the body (separated by the midline) is mutant, allowing for direct comparison of mutant and control cells in the same animal. Helen uses a variety of techniques to identify ‘convergent phenotypes,’ including RNAseq, in situ hybridization, and immunostaining. In this way, Helen’s work is aimed at identifying phenotypes most relevant to ASD pathology to provide a path forward for understanding the molecular mechanisms underlying ASD.

Helen Willsey, PhD is a Postdoctoral Fellow at UCSF Medical School. She has extensive experience in genetic analysis, phenotyping, Drosophila husbandry, Xenopus husbandry, injections, dissections, immunostaining, confocal microscopy, 2-photon microscopy, RNA in situ hybridization, molecular biology, cloning, mentoring, and teaching.

Future of Functional Longevity

A historic revolution in the longevity field is underway. Learn about the latest advances and initiatives in the aging field including a clinical trial being organized by two UCSF professors Elissa Epel and Wendy Mendez.

ARVE Error: Mode: lazyload not available (ARVE Pro not active?), switching to normal mode

Dr. Joon Yun, President of Palo Alto Investors, an investment management firm founded in 1989 with $1.8 billion in assets invested in healthcare. Board certified in Radiology, Joon served on the clinical faculty at Stanford from 2000-2006. He received his B.A. from Harvard, M.D. from Duke Medical School, and clinical training at Stanford. Joon has served on several corporate and non-profit boards, and has published dozens of patents, scientific articles, and business essays. He is a contributor to Forbes, and is the health editor for Evolution magazine. Joon recently agreed to donate a $1million Palo Alto Prize to reverse the aging process.

Using Big Data to Uncover the Hidden Genetic Network of Disease

Nevan Krogan, PhD, thinks genomics has brought us closer to a revolution in cancer treatment than most geneticists even realize. “There’s been a tsunami of genetic data about different cancers.” But despite this rising tide of knowledge, breakthroughs in cancer treatment have been slow to materialize. In part, this is because all of the new data have only gone to show cancer’s staggering diversity: Even a single tumor can contain a unique profile of thousands of genetic mutations, leaving researchers to puzzle out which are disease drivers and which are just along for the ride. Instead of collecting yet more data, Krogan believes researchers need to look harder at the connections hidden in the data they already have. He and his colleagues think differently about where cancer comes from. Rather than see the disease as a problem caused by one or more gene mutations, they see cancer as a breakdown of large, interconnected gene networks. Different genes can malfunction in different people and still produce the same end result because of how they affect the larger networks they are part of, he says. This is why when researchers look at the cancer genomes of two people with very similar lung tumors, for instance, they may see drastically different mutation profiles.

Photo by Susan Merrell

Nevan Krogan, PhD is a professor in the Department of Cellular and Molecular Pharmacology at UCSF and a senior investigator at the J. David Gladstone Institutes. He is also the Director of the Quantitative Biosciences Institute, (QBI), which focuses on developing and using quantitative approaches to study basic biological mechanisms, often related to disease areas. He serves as Director of The HARC Center, an NIH-funded collaborative group that focuses on the structural characterization of HIV-human protein complexes. Krogan’s research is focused on using quantitative system approaches to help understand complex biological and biomedical problems. He has authored over 200 papers in the field of molecular biology and has given over 200 lectures and seminars around the world. He is also the Principal Investigator of the Krogan Lab which focuses on high-throughput network biology to derive mechanistic insights into cellular processes and disease conditions, with a particular emphasis on pathogenesis, cancer, psychiatric disorders and heart disease. The Krogan Lab located at the Quantitative Biosciences Institute (QBI) of UCSF and the Gladstone Institutes.

Investing in Innovation from an Institutional Perspective

Leading industry focused investors who leverage their talent, influence and capital to identify and grow businesses will share their investment approach and industry insights.

Gary Magnant is CEO of Triple Sharp Venture Engineering, LLC. He is the Co-Founder and former CEO of Thrive Bioscience, Inc., Sage Science, Inc. and Owl Scientific (now part of Thermo Fisher), and the former Vice President of MJ Research (now Bio-Rad). Gary holds numerous patents and inventions and numerous bioscience related board positions. He is also the Co-founder and former President of ActivBiotics (Lexington, MA) and ThermoCeramix (Montreal, Canada), as well as the former Chairman, Trustee, Hallowell Awardee, of Stoneridge, a private Montessori school in Beverly, MA (now Harborlight-Stoneridge). Gary believes that there is a better way to start life science companies than traditional VC. His experience in founding and building Thrive Bioscience in May 2014 was so personally and professionally transformative, that he founded Triple Sharp Venture Engineering to help construct other life science companies. Triple Sharp’s mission constructs new companies with two aims. First, the company strives to own and efficiently manage risk, and second, the company build super-engaged management teams. Triple Sharp Venture Engineering navigates its client companies through growth, financings, and exits.

Steve Massocca is Managing Director of the Wedbush Equity Management team. He is also the portfolio manager for the Wedbush Hedged Dividend Fund, LP. Mr. Massocca has 30+ years of industry experience. Steve began his career at Dean Witter Reynolds (agency trading) and also worked at Montgomery Securities (principal trading) and Volpe, Welty and Co, LLC (head of trading). Steve founded, operated and grew Pacific Growth Equities, LLC to 120 employees as co-CEO before it was purchased by Wedbush Securities in 2009. Steve has a BA in Accounting from Golden Gate University.

Eric Rice, Ph.D is Managing Director and Mult-Asset Portfolio Manager of Wellington Management, which offers comprehensive investment management capabilities that span nearly all segments of the global capital markets. US$969 billion of client assets under management; 13 offices worldwide; 2,150+ clients; 55+ countries in which clients are based. Eric is the architect of Wellington Management’s social impact strategy. He manages our flagship Global Impact Portfolio and is a thought leader for the development of social impact and other thematic investment ideas that support the firm’s portfolio managers and analysts. Eric has a long history as an analyst on multiple investment portfolios, conducting investment research that ranges across all geographies and macro-level issues, and incorporating investment themes into portfolios at the security level. Eric’s passion for social impact developed through his work as diplomat in Rwanda with the US Department of State, and deepened during his doctoral studies and his position as a country economist at the World Bank. Prior to joining the firm in 1997, Eric was the head of Emerging Markets Research at Standard & Poor’s Global Insight (1995 – 1997). From 1990 to 1995, he worked at the World Bank as country economist for Mexico and Zimbabwe, as well as other assignments on Malaysia, the Philippines, Bulgaria, and Romania. Eric received his PhD (1990) from Harvard University, and his AB from the University of California at Berkeley, both in economics.

Robert Smith entered Wall Street with lessons passed down from four generations of family members who worked in the investment industry before him. Over the course of his career, he managed sales and trading teams at leading financial institutions, and built capital markets and international equities businesses. In 2014, Robert founded ICV to bring together his network of Family Offices and Fund Investors to evaluate opportunities that create a social impact beyond a financial return. He serves as Business Strategy Advisor to New Frontier Bio, a multi-asset holding company, which leverages the long-term involvement of the Kennedy family in healthcare to identify, finance and develop novel medical technologies from inception through clinical proof of concept. Robert serves as a member of the President’s Advisory Board of Thomas Jefferson University and Jefferson Health, 16th on U.S. News & World Report’s 2017-2018 Best Hospitals Honor Roll. He serves on the Sustainable Investing Advisory Board of the United Nations Capital Development Fund (UNCDF), which makes public and private finance work for the poor in the world’s 47 Least Developed Countries (LDCs). Robert is Senior Advisor for Fundraising and Partnerships to the Permanent Secretariat of the World Summit of Nobel Peace Laureates. Carrying on the mission of his family to provide “inspirational and tangible help for young people,” he serves as a board member of the Chaeli Foundation, Childhood Cancer Kids, Children’s Village and Tuesday’s Children. He is Senior Advisor to the Africa Rising Foundation founded by Ndaba and Kweku Mandela, grandsons of Nelson Mandela. Robert is also President and a member of the Board of Directors of The Harmon Foundation, a private foundation established in 1922 by his great, great grandfather, William E. Harmon, who operated the largest real estate company in the world at the turn of the 20th century, created the mortgage and college loans, fueled the Harlem Renaissance and donated to thousands of nonprofits over his lifetime “to bring smiles and tender thoughts to the great in heart in high and low places, and to comfort and cheer those who do exceptional things or suffer.” In 2018, Robert was recognized as one of The 100 Visionary Leaders by Real Leaders Magazine, alongside Bill Gates, Muhammad Yunus, President Juan Santos, Mikhail Gorbachev, Leonardo DiCaprio and many others who are leading us towards a better world. He was also inducted as a member of Evolutionary Leaders, a network of people who feel a sense of urgency about the state of our world and are forging a movement for the conscious evolution of humanity.

Dr. Joon Yun, President of Palo Alto Investors, an investment management firm founded in 1989 with $1.8 billion in assets invested in healthcare. Board certified in Radiology, Joon served on the clinical faculty at Stanford from 2000-2006. He received his B.A. from Harvard, M.D. from Duke Medical School, and clinical training at Stanford. Joon has served on several corporate and non-profit boards, and has published dozens of patents, scientific articles, and business essays. He is a contributor to Forbes, and is the health editor for Evolution magazine. Joon recently agreed to donate a $1million Palo Alto Prize to reverse the aging process.

Women Leaders in Healthcare

Championing women’s health, equality and empowerment, women leaders in healthcare will discuss health and economic empowerment, including productive resources and active participation in governance and decision-making.

“We’re in the midst of an extraordinary fight and we need every ounce of manpower we can muster, but the good news is, should we succeed, we’ll have turned the most awful paradigm that we know on it’s head… that is to say, the inevitability of death.”

– Laura Deming

Laura Deming, is Partner of The Longevity Fund, which finds and funds companies that aim to extend the period of healthy human life and ameliorate age-related decline in physical function. Managed by former executives and fund managers with a track record of success in the pharma industry, the Fund seeks to capitalize on innovation-based opportunity wherever it finds it. When she was 8, Laura realized that we were all going to die of a disease called aging. Ever since, her driving passion has been to slow aging and eliminate age-related disease. She started working in a biogerontology lab when she was 12, and matriculated at MIT when she was 14. At 17, she was one of the youngest 20under20 fellows awarded $100,000 by Peter Thiel to pursue her venture full time. Laura is currently a full-time partner at The Longevity Fund, an early stage venture capital fund backing companies which target the aging process to treat disease, with investments in gene editing, small molecule therapeutics, and novel methods to treat disease.

Julia P. Gregory is Chairman and CEO of Isometry Advisors. She received her M.B.A. from The Wharton School of The University of Pennsylvania and her B.A. in International Affairs with a minor in International Economics from George Washington University’s Elliott School of International Affairs where she was elected to Phi Beta Kappa. She is currently Chairman and CEO of Isometry Advisors, Inc., a biotechnology financial and management advisory firm, has 16 years of biotechnology executive management experience and 20 years of investment banking experience.

Deepa Pakianathan, PhD is Managing Member at Delphi Ventures and leads all of the firm’s biotechnology investment activities. She currently serves on the boards of Alder Biopharmaceuticals (Nasdaq: ALDR), Calithera Biosciences (Nasdaq: CALA), ForSight: Vision5, Karyopharm Therapeutics (Nasdaq: KPTI) and Oncomed Pharmaceuticals (Nasdaq OMED). Deepa previously served on the boards of Salmedix (acquired by Cephalon), Ilypsa (acquired by Amgen), Proteolix (acquired by Amgen), PTC Therapeutics (Nasdaq: PTCT) and Relypsa (Nasdaq: RYLP). She also led the investments in Cardeas Pharma, KAI Pharmaceuticals (acquired by Amgen), and PIPE investment in Seattle Genetics (Nasdaq: SGEN). Deepa joined Delpha in 2001 to build and lead the firm’s biotechnology investment practice which focuses on drug discovery and development platform technologies that have resulted in multiple novel drugs, including six that are commercially marketed. Prior to joining Delphi, Deepa was a Vice President in the healthcare group at J.P. Morgan where she was involved in several large healthcare M&A transactions and lead public offerings for biotechnology companies that raised over $9 billion. Prior to that, she was a biotechnology research analyst at Genesis Merchant Group. She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997. She serves as Vice-Chair of the San Francisco Conservatory of Music’s Board of Trustees. Deepa received her Ph.D. and MS from Wake Forest University and her MSc and BSc from the University of Bombay.

Cami Samuels joined Venrock in 2014 and focuses on healthcare with an emphasis on biotech, medical devices, and consumer health. She currently serves on the board of Spirox Medical and Unity Biotechnology, and recently stepped off the board of REGENXBIO (RGNX). Prior to Venrock, Cami was a Managing Director at Versant Ventures for a decade where she led investments in Achaogen (AKAO), Kythera (KYTH), Novacardia (acquired by Merck), and ParAllele (acquired by Affymetrix), among others. She was also a board observer at several companies including Genomic Health (GHDX), Fluidigm (FLDM), and Syrrx (acquired by Takeda). Before Versant, she was responsible for business development at Tularik, Inc. (acquired by Amgen) where she in-licensed two of the company’s clinical-stage products and led Tularik’s Technology Acquisition Group. Before Tularik, Cami worked in corporate development at Genzyme and Millennium Predictive Medicine, and was a management consultant to healthcare and biotech companies at LEK Consulting. Cami earned her Bachelor’s degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar. In 2002, The Aspen Institute named Camille a Henry Crown Fellow..

Innovative Cancer Treatment

Today’s cancer care looks beyond the organ in which a tumor arises by personalizing treatment to the unique genetic signature of each individual and tumor. Our cancer experts will teach you to use computational genomics sequencing techniques, which provide a road map for personal cancer treatment and prevention plans. Witness a live molecular tumor board and the multidisciplinary brain power engaged in solving the most complex cancer patient cases.

Eric Collisson, MD is Associate Professor at UCSF. He is a medical oncologist with a specific interest in the genomics of cancer. His laboratory uses a variety of techniques to interrogate three basic themes in the biology and clinical behavior of these deadly cancers: (1) intra- patient tumor heterogeneity at the temporal and anatomic levels, (2) inter-patient heterogeneity between different patients, and (3) tumor-microenvironmental interactions. The lab uses a combination of genetically engineered mouse models, cell lines, and clinically derived samples to interrogate multiple genomic outputs with a focus on genomic DNA and mRNA.

Larry Fong, MD is Leader, Cancer Immunotherapy Program and Co-Leader of the Cancer Immunology Program at the UCSF Helen Diller Family Comprehensive Cancer Center. He is the Efim Guzik Distinguished Professor in Cancer Biology. He has focused on cancer immunotherapy throughout his career. After completing Oncology Fellowship at Stanford, he completed post-doctoral training with Drs. Ed Engleman and Mark Davis focused on tumor immunology. He then began his independent research program at UCSF and has continued to focus on how the immune system interacts with cancer as well as developing tumor immunotherapies in both mouse models and in patients. UCSF described the immunogenicity of prostate acid phosphatase (PAP), which is the target antigen for sipuleucel-T, now an FDA-approved immunotherapy for prostate cancer. UCSF was also involved with the first-in-man clinical trials with ipilimumab, an anti-CTLA4 antibody that is now FDA approved for melanoma. USCF continues to investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor immunity in patients. Fong also served on multiple NIH study sections and on the NCI Steering Committees for Genitourinary Cancer (GUSC) and Investigational Drugs (IDSC)-Immunotherapy Task Force. He also served on the program committees for ASCO and AACR and on faculty for the AACR/ASCO Vail Methods in Clinical Research Workshop. Fong is the site PI at UCSF for the NCI-sponsored Cancer Immunotherapy Trials Network (CITN).

Ira Mellman, PhD is Vice President, Cancer Immunology of Genentech. Mellman’s work has examined the role of endocytosis in cell metabolism and human disease. He was among the first to characterize the endosomal system. Later projects include investigation of LDL cholesterol receptor internalization, cellular sorting machinery, and the cellular basis for immunity. He is an authority on the cell biological mechanisms and function of dendritic cells, the cell type responsible for initiating the immune response, an interest that dates back to his postdoctoral period at Rockefeller University in the lab of Ralph Steinman, who won the Nobel Prize in 2011 for his discovery of dendritic cells.

Mark Moasser, MD runs a translational cancer research program at UCSF focused on translating our understanding of tyrosine kinase signaling in epithelial cancers into better treatments for patients with cancer. My training and career encompasses both the clinical practice of Medical Oncology and clinical research in Oncology, as well as leading a scientific laboratory research program. This hybrid clinical-scientific involvement gives me the exposure, knowledge base, and insights required for the optimal pursuit of translational cancer research. I pursue clinically relevant scientific questions at the bench, and I translate our scientific discoveries into clinical trials. I have a track record of several clinical trials emerging directly from our laboratory discoveries. My role as co-chair of the early phase clinical trials unit puts me at the front lines of clinical drug development, aware of the challenges, early results, and pipelines.

Pamela Munster, MD is Professor of the Department of Medicine (Hematology/Oncology) and Director, Early Phase Clinical Trials Unit, Co-leader of the Center for BRCA Research, and Leader, Experimental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center.

Nelson Teng, MD is Associate Professor of Obstetrics and Gynecology (Oncology) of Stanford University. He has extensive scientific and medical insight with respect to cancer, women’s health, surgery and monoclonal antibodies. He also has a vast network of relationships with leading scientists and physicians throughout the world and has been the founder and director of multiple biotechnology companies. Since 1986, Nelson has been chief of gynecologic oncology at Stanford University’s School of Medicine. Nelson is a named inventor on fifteen patents and is an author of more than 100 publications. Over the past 20 years, the scientific research at Nelson’s laboratory at Stanford University has focused on cancer biology and gynecologic diseases. His laboratory has created numerous monoclonal antibodies of clinical interest, including the first human therapeutic monoclonal antibody to be taken into clinical trials. Nelson has also been a principal investigator for more than 30 cancer clinical trials. Among his many professional honors, Nelson has been honorary senior registrar at Hammersmith Hospital (London), Royal Postgraduate College and research scientist at the Massachusetts Institute of Technology. He is a fellow of the American College of Surgeons and the American College of Obstetricians and Gynecologists, former president of the Western Association of Gynecologic Oncologists and former chairman of the uterine and cervical cancer committee and member of both the ovarian cancer committee and the cervical cancer screening committee of the National Comprehensive Cancer Network. Nelson has also served on various committees within the Gynecologic Oncology Group, a national clinical trial consortium sponsored by the National Cancer Institute. Nelson is board certified in gynecology, gynecologic oncology and obstetrics. In addition to his many academic and clinical accomplishments, Nelson has also been an active entrepreneur over the past twenty years. He was a founder of several companies with Barr, including women’s health care company Adeza Biomedical (ADZA), biotech company Univax Biologics (IPO, then acquired by NABI) and women’s health care company Vesta (acquired by Pfizer). He has also served as vice president of research at Adeza Biomedical. Nelson also has extensive experience in Asia and, with respect to biotechnology matters, has been an advisor to Asian governments and Asian-based venture capital funds such as Vertex and Mingly Capital.

Orthopedic Bioengineering

The University of California at San Francisco Laboratory for Orthopaedic Bioengineering is directed by Jeffrey C. Lotz, Ph.D. The laboratory is located within the Department of Orthopaedic Surgery and aims to understand the biomechanics and biology of the lumbar spine and intervertebral disc in both health and disease. A number of research programs in this area include: theoretical and experimental development of material laws for disc tissues; finite element simulations of disc and vertebral body response to in vivo loading; animal models to clarify the mechanisms of disc degeneration and repair; animal models to clarify the relationship between disc degeneration and pain; investigation of novel surgical interventions meant to treat back pain; and tissue engineering of fibro-cartilaginous tissues.

Jeffrey Lotz, PhD holds the David S. Bradford, MD, Endowed Chair in Orthopaedic Surgery and vice chair for research. He has earned several awards for spine research, and serves as a deputy editor for the journal Spine. Dr. Lotz is the founding director of the UCSF Core Center for Musculoskeletal Biology in Medicine and the NSF Center for Disruptive Musculoskeletal Innovations, and corresponding PI for the newly-established Center for Dental, Oral and Craniofacial Tissue and Organ Regeneration (C-DOCTOR). He has expertise in spine biomechanics, intervertebral disc biology, and tissue engineering. His laboratory work focuses on identifying mechanisms of disc degeneration, developing novel diagnostics and therapies for low back pain, and the biomechanics of spinal instrumentation.

Regenerative Medicine: Stem Cells

The fountain of youth can be found in a UCSF lab, where researchers are exploring the biology of aging. From muscle to blood to neurons, scientists are finding the keys to understanding and ultimately reversing aging. Learn and experiment with the innovative scientists who explore how exercise reverses muscle aging, how women can better predict their reproductive age, and how factors in our bodies can be directed to preserve our brains.

ARVE Error: Mode: lazyload not available (ARVE Pro not active?), switching to normal mode

Sarah Knox, PhD is Associate Professor, Department of Cell and Tissue Biology of the UCSF School of Medicine. Her goal is to investigate how neuronal-epithelial interactions control organogenesis and regeneration. Her work primarily utilizes the mouse embryonic submandibular gland ex vivo model system to examine the role of the parasympathetic ganglion in epithelial branching morphogenesis and regeneration. The submandibular gland has an autonomic ganglion located in and around the glandular epithelium from the earliest stages of development, and remains with the gland after dissection for ex vivo organ culture. This makes the salivary gland an exceptional model for understanding the influence of the peripheral nervous system on organogenesis and repair processes.

CEO Roundtable: Neotherma Oncology and Nexeon Medsystems

Business leaders of emerging growth companies share how they are tackling some of the most complex challenges in human health.

Moderator

Gary Magnant is CEO of ICV Venture Engineering Fund I, LLC. He is the Co-Founder and former CEO of Thrive Bioscience, Inc., Sage Science, Inc. and Owl Scientific (now part of Thermo Fisher), and the former Vice President of MJ Research (now Bio-Rad). Gary holds numerous patents and inventions and numerous bioscience related board positions. He is also the Co-founder and former President of ActivBiotics (Lexington, MA) and ThermoCeramix (Montreal, Canada), as well as the former Chairman, Trustee, Hallowell Awardee, of Stoneridge, a private Montessori school in Beverly, MA (now Harborlight-Stoneridge). Gary believes that there is a better way to start life science companies than traditional VC. His experience in founding and building Thrive Bioscience in May 2014 was so personally and professionally transformative, that he founded Triple Sharp Venture Engineering to help construct other life science companies. Triple Sharp’s mission constructs new companies with two aims. First, the company strives to own and efficiently manage risk, and second, the company build super-engaged management teams. Triple Sharp Venture Engineering navigates its client companies through growth, financings, and exits.

Dr. Michael Wandell is CEO of Neotherma Oncology. Dr. Wandell is a medical device executive and clinical pharmacologist with a record of efficiently delivering novel, cutting edge medical products to global markets. He acknowledged for applying sound judgment based on a strong ethical commitment to a deep knowledge of GxP requirements, design control, and global regulatory ecosystems to win rapid regulatory approvals and market adoption. As VP or chief scientific officer of several multinational device companies, he has submitted a number of novel FDA PMAs, BLAs, and PLAs for first-in-class products including the first HIV blood screening system, consumer use HIV and hepatitis C systems, additionally winning registration in 22 countries including Koseisho (Japan’s MHLW) approval for the first HIV blood screening medical device in Japan. He has designed and successfully conducted large multi-center clinical trials in U.S., Canada, Australia, Japan and EU, and won PMA approval for a consumer-use hepatitis C testing/counseling/medical referral systems in 141 days.

Discussion: How to Ensure Innovative Technologies Improve Efficacy and Quality of Cancer Care

Taking a medical device from concept to clinic: What entrepreneurs, biotech Investors, and inventers need to keep in mind.

To effectively integrate cutting edge technology: listen to clinicians and patients.
Commit to an evidenced-based medicine approach.
Focus on improving both clinical benefit and health economics (cost effectiveness).
Navigating a new regulatory environment with quality framework for continuous improvement

Nexeon Medsystems

Will Rosellini, JD, MBA is Chairman and CEO of Nexeon Medsystems, a global medical device company focused on providing innovative neurostimulation products that improve the quality of life of patients suffering from debilitating neurological disease. Rosellini, a former minor-league pitcher, holds five master’s degrees in addition to a law degree. He is a 15-year veteran of the neurotechnology space and has expertise in accelerating the development of emerging technologies with minimal at-risk capital. He previously founded and led Lexington Technology Group, LLC, a database company commercializing a database solution with an exit to (“DSS” NYSE) Sarif Biomedical LLC, a stereotactic microsurgery company exit to (“MARA” NSDQ) and Emeritus Clinical Solutions (Acquired). He became a board member of Marathon Patent Group (“MARA”) in 2013. Rosellini also founded Microtransponder in 2006, in 2012, Rosellini left his position as CEO at Microtransponder after temporarily losing his voice to thyroid cancer. Will has been serving as the Chairman and CEO of Nexeon MedSystems since January 2016.

ARVE Error: Mode: lazyload not available (ARVE Pro not active?), switching to normal mode

Philanthropy

UCSF: The Campaign launches with a goal to raise $5B to tackle the grand challenges.

Your Donations Make a Difference.
Care, heal, teach, discover: That’s what your gifts empower UCSF to do. Your generosity keeps UCSF nimble and innovative, able to take on urgent challenges and promising opportunities.

Donate

Venue

UCSF Medical Center at Mission Bay
William J. Rutter Center
Fisher Banquet Hall
Address: 1675 Owens Street, San Francisco, CA 94158
Phone: (415) 353-3000

Directions

Mission Bay is home to UCSF Benioff Children’s Hospital San Francisco, UCSF Betty Irene Moore Women’s Hospital and UCSF Bakar Cancer Hospital, in addition to numerous outpatient services for both children and adults.

Agenda

January 11

09:00 AM		Registration & Breakfast
START	END	Fisher Banquet Hall
09:25	9:30	Welcome Remarks: Joe Krovoza, JD, Director of Development for Cancer Programs
09:30	10:15	Neuroscience of Depression \| Addiction: Vikaas Sohal, MD, PhD, Josh Berke, PhD, Danielle Ramo, PhD, Shawn Singh of Vistagen Therapeutics, Andrew Krystal, MD
10:15	10:20	Break
10:20	10:40	Investing in Innovation from an Institutional Perspective: Gary Magnant of ICV, Steve Massocca of Wedbush, Eric Rice of Wellington Management, Robert Smith of ICV, Dr. Joon Yun of Palo Alto Investors
11:00	11:30	New Pathways for Neurology: Autism and the Brain: Helen Willsey, PhD
11:30	12:00	Virtual Reality, Real Science: Joaquin Anguera, PhD
12:00	1:30	Networking Luncheon \| Speaker Presentations
12:15	12:30	Big Ideas to Market: Barry Selick, MD and Thomas Quinlan of Reed Smith
12:30	12:50	Leadership Spotlight: Mark Laret, President and CEO of UCSF Health and Jim Burness
12:50	1:10	Future of Functional Longevity: Dr. Joon Yun, President of Palo Alto Investors
1:30	2:15	Women Leaders in Healthcare: Laura Deming of The Longevity Fund, Julia Gregory of Isometry Advisors, Deepa Pakianathan, PhD of Delphi Ventures, Cami Samuels of Venrock
2:20	3:05	Innovative Cancer Treatment: Eric Collisson, MD, Larry Fong, MD, Mark Moasser, MD and Nelson Teng, MD
3:10	3:25	Orthopedic Bioengineering: Jeffrey Lotz, PhD
3:25	3:40	Regenerative Medicine: Stem Cells: Sarah Knox, PhD
3:45	4:00	Using Big Data to Uncover the Hidden Genetic Network of Disease: Nevan Krogan, PhD
4:00	4:30	CEO Roundtable: Neotherma Oncology, Michael Wandell & Nexeon Medsystems, Daniel Powell
4:30	4:40	Closing Remarks: Robert Smith, Founder of ICV
4:40	6:00	Networking Reception	COMPANY PRESENTATION